Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.69 |
| ▸ | AOC2 | O75106 | 4/20 | 0.69 |
| ▸ | MAOA | P21397 | 3/20 | 0.69 |
| ▸ | DAO | P14920 | 2/20 | 0.69 |
| ▸ | AOC3 | Q16853 | 15/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20709044 | 1.00 | MAOB (0.69) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL20709010 | 0.84 | MAOB (0.47) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL1294791 | 0.81 | MAOB (1.00) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL1294789 | 0.81 | MAOB (1.00) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL1294793 | 0.81 | MAOB (1.00) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL1295177 | 0.80 | MAOB (0.73) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL1294848 | 0.80 | MAOB (0.73) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL1295543 | 0.80 | MAOB (0.73) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL1294157 | 0.80 | MAOB (0.73) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL1295031 | 0.80 | MAOB (0.73) | MAOBAOC2MAOADAOAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257342-A1 | HALOALLYLAMINE DUAL AMINE OXIDASE INHIBITORS | PHARMAXIS LTD. (AU) | 2023-08-17 | — | — | US | disclosed |
| EP-3438087-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2019-02-06 | — | — | EP | disclosed |
| EP-2844637-B1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257342-A1 | HALOALLYLAMINE DUAL AMINE OXIDASE INHIBITORS | AOC2, AOC3, AOC1 | MAOB 4/4885AOC2 1/4885MAOA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.